Treatment, Medication & Supplement Directory

A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.

Directory explains “what it is.”Guides explain how owners can discuss, use, monitor, or prepare for a treatment option with veterinary guidance.

4 entriesShowing 1–4

Calm dog receiving a monitored intravenous treatment in a veterinary clinic

Named profile Tanovea (Rabacfosadine): FDA-Approved Injectable Canine Lymphoma TherapyRepresentative category illustration – no product packaging is shown.

Chemotherapy · Prescription Drug · Single-agent Chemotherapy · Tanovea · Dogs · After Chemotherapy · Before Chemotherapy

Tanovea (Rabacfosadine): FDA-Approved Injectable Canine Lymphoma Therapy

Rabacfosadine is a canine lymphoma drug whose current official label, patient selection, cumulative risks, and availability must be verified before use.

Veterinary team coordinating a medication schedule for a dog

Named profile Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor TherapyRepresentative category illustration – no product packaging is shown.

Prescription Drug · Targeted Therapy · Stelfonta · Dogs · After Targeted Therapy · During Targeted Therapy · Published Study

Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor Therapy

Stelfonta is an FDA-approved intratumoral treatment for narrowly defined canine mast cell tumors, with important current warnings about degranulation, wounds, pain, tissue loss, amputation, and death.

Veterinarian reviewing an immune pathway concept and an unbranded biologic treatment with a dog caregiver

Named profile Gilvetmab: Canine PD-1 Immunotherapy and Conditional-Licence ProfileRepresentative category illustration – no product packaging is shown.

Immunotherapy · Prescription Drug · Gilvetmab · Dogs · During Targeted Therapy · New Diagnosis · Published Study

Gilvetmab: Canine PD-1 Immunotherapy and Conditional-Licence Profile

gilvetmab is covered as caninized anti-pd-1 monoclonal antibody immune-checkpoint inhibitor, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Caregiver and veterinary professional reviewing symptom observations for a dog

Named profile H1 and H2 Blockade Around Mast-Cell Degranulation RiskRepresentative category illustration – no product packaging is shown.

Prescription Drug · Supportive-care medicine · Mast-cell mediator blockade · Dogs · During Targeted Therapy · Veterinary Clinical Use · Label-linked companion-medication context

H1 and H2 Blockade Around Mast-Cell Degranulation Risk

H1-receptor and H2-receptor blocking companion medicines is covered as protocol-linked supportive medicines; not direct antitumour treatment, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led…

Treatment, Medication & Supplement Directory

Filter

Tanovea (Rabacfosadine): FDA-Approved Injectable Canine Lymphoma Therapy

Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor Therapy

Gilvetmab: Canine PD-1 Immunotherapy and Conditional-Licence Profile

H1 and H2 Blockade Around Mast-Cell Degranulation Risk